<DOC>
	<DOCNO>NCT01319981</DOCNO>
	<brief_summary>The goal clinical research study learn intensive chemotherapy ( hyper-CVAD therapy ) give combination liposomal vincristine ( Marqibo ) , addition rituximab patient CD20 positive and/or imatinib dasatinib patient Philadelphia ( Ph ) chromosome , help control ALL lymphoblastic lymphoma . The safety treatment also study . CD20 protein `` marker '' find leukemia lymphoma cell .</brief_summary>
	<brief_title>Hyper-CVAD With Liposomal Vincristine Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>The Study Drugs : Adriamycin ( doxorubicin ) design stop growth cancer cell , may cause cell die . Cyclophosphamide design disrupt multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . Cytarabine ( Ara-C ) design insert DNA ( genetic material cell ) cancer cell stop DNA repairing . Dexamethasone corticosteroid similar natural hormone make body . Methotrexate design disrupt cell make repair DNA `` copying '' . Vincristine design disrupt multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . Liposomal Vincristine ( Marqibo ) design help vincristine stay bloodstream long time , specifically target tumor tissue , deliver drug tumor site longer period time . This may increase effective drug low risk possible side effect healthy , non-tumor tissue . Rituximab monoclonal antibody design attach leukemia cell activate series event may cause cancer cell die . Tyrosine Kinase Inhibitors ( TKI -- Imatinib Dasatinib ) Imatinib drug design block cancer cell grow divide . Dasatinib design block protein cancer may need grow , survive , spread . Study Groups : If find eligible take part study , assign 1 2 group , base already perform diagnostic test certain protein , call CD20 . - If test positive CD20 , receive hyper-CVAD therapy plus rituximab . - If test negative CD20 , receive hyper-CVAD therapy . In addition , patient Philadelphia chromosome ( consider Philadelphia-positive Ph+ ) receive imatinib dasatinib either group . The study doctor decide drug participant receive . Study Drug Administration : Hyper-CVAD therapy combination 7 chemotherapy drug : combination adriamycin ( doxorubicin ) , cyclophosphamide , liposomal vincristine , alternate combination cytarabine ( Ara-C ) , dexamethasone , methotrexate , liposomal vincristine . You receive 2 different study drug combination 21-28 day `` course . '' You begin Course A treatment alternate Course B treatment every course . You stay overnight hospital first 4-5 day course . For Course A treatment , receive cyclophosphamide , liposomal vincristine , doxorubicin , dexamethasone . For Course B treatment , receive methotrexate , cytarabine , liposomal vincristine . Courses treatment study continue alternate switch Course A study drug combination odd number course ( 3 , 5 , 7 ) Course B study drug combination even number course ( 4 , 6 , 8 ) total 8 course . While study , dose study drug combination give central venous catheter ( CVC ) . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . Course 1 : On Days 1 , 2 , 3 receive cyclophosphamide vein 24 hour , mesna vein continuously 24 hour , liposomal vincristine vein 1 hour +/- 30 minute ( Day 1 ) . Mesna give help prevent blood urine , sometimes cause cyclophosphamide . On Days 2 7 , methotrexate cytarabine give intrathecal ( IT ) infusion directly spinal fluid low risk disease spread brain . On Day 4 , receive doxorubicin vein 24 hour . On Day 5 6 , G-CSF inject skin help recovery bone marrow cell recovery 24 hour dose study drug . On Day 8 , receive liposomal vincristine vein 1 hour +/- 30 minute . On Days 1-4 Days 11-14 , dexamethasone give mouth glass water vein short infusion . CD20 positive patient also receive rituximab vein 6 hour , Days 1 8 , addition receive study drug , describe . If CD20 negative , receive rituximab . Ph+ participant receive imatinib mouth breakfast large glass water ( 8 ounce ) dasatinib mouth Days 1-14 Course 1 . Course 2 : On Day 1 , receive methotrexate vein 24 hour . On Days 2 3 , receive cytarabine vein 2 hour every 12 hour total 4 dos . You also give citrovorum factor ( leucovorin ) vein mouth help prevent possible side effect methotrexate . On Day 5 6 , G-CSF inject skin help bone marrow recovery 24 hour dose study drug . On Days 5 8 , cytarabine methotrexate give IT infusion lower risk disease spread brain . CD20 positive patient also receive rituximab vein 4 hour , Days 1 8 , addition receive study drug , describe . If CD20 negative , receive rituximab . Ph+ participant receive imatinib mouth breakfast large glass water ( 8 ounce ) every day Courses 2-8 . Dasatinib give mouth every day Courses 2-8 . Course 1 Study Visits : - Blood ( 5 teaspoon time ) drawn weekly routine test . - During Week 2 3 4 , bone marrow aspirate perform check status disease . - At end Course 1 , study doctor think need , chest X-ray CT scan perform check status disease . If study doctor think need , test may repeat time receive study drug combination . Radiation Treatment : If lymphoblastic lymphoma enlarge lymph gland chest , may receive radiation treatment chest complete 8 course therapy begin maintenance therapy . If receive radiation therapy chest , study doctor discuss procedure know risk detail , give separate consent form sign . Maintenance Therapy -- Non-Ph+ Participants : After complete 8 course study drug combination , begin maintenance therapy total 30 month , interrupt 2 period intensive chemotherapy consolidation course . Every month maintenance therapy : - You take 6-mercaptopurine every day mouth . - You receive methotrexate vein mouth 1 time every week . - You receive liposomal vincristine vein 1 hour +/- 30 minute Day 1 . - You take dexamethasone mouth Days 1-5 month . First intensive chemotherapy consolidation course : - Six ( 6 ) month begin maintenance therapy , receive two month intensive chemotherapy course . - First , receive cyclophosphamide , liposomal vincristine , doxorubicin , dexamethasone ( similar Course 1 ) Month 6 therapy . - About one ( 1 ) month later , receive methotrexate vein ( low dose give Course 2 ) Day 1 pegylated asparaginase vein 2 hour Day 2 . You give drug 1 time week total 4 week Month 7 therapy . About eighteen ( 18 ) month begin maintenance therapy , repeat intensive chemotherapy course describe . Maintenance Therapy -- Ph+ Participants : After complete 8 course study drug combination , begin maintenance chemotherapy plus imatinib dasatinib . Maintenance chemotherapy give total 24 month , interrupt 2 period intensive chemotherapy course imatinib dasatinib 6 13 month start maintenance . You continue receive imatinib dasatinib every day point , unless intolerable side effect occur . Every month maintenance therapy : - You take imatinib dasatinib every day mouth . - You receive liposomal vincristine vein 1 hour +/- 30 minute Day 1 . - You take dexamethasone mouth Days 1-5 month . Intensive chemotherapy consolidation course : Â°At six ( 6 ) eighteen ( 18 ) month begin maintenance therapy , receive two month intensive chemotherapy course . You receive cyclophosphamide , liposomal vincristine , doxorubicin , dexamethasone imatinib dasatinib ( similar Course 1 ) . If disease CD20 positive , may receive rituximab . Blood Tests : During maintenance therapy intensive consolidation therapy , blood ( 5 teaspoon ) draw every 4 week +/- 4 week routine test . After intensive chemotherapy consolidation , long continue receive maintenance therapy , blood ( 5 teaspoon ) draw every 4 week +/- 4 week , maintenance therapy complete : Additional Tests Study : Every 3-6 month : - You bone marrow biopsy perform check status disease . - If mediastinal disease , chest x-ray CT scan . Length Study : You receive 8 course therapy . If Ph+ , continue receive maintenance therapy 30 month . If Ph+ , continue receive maintenance therapy 24 month , follow imatinib dasatinib alone indefinitely . You take study disease get bad , experience intolerable side effect , study doctor think best interest . This investigational study . Liposomal vincristine FDA approve treatment patient CLL relapse least 2 time . All study drug use study FDA approve commercially available . The combination liposomal vincristine study drug also use research . Up 65 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Newly diagnose previously untreated ALL lymphoblastic lymphoma &gt; /= 18 year old . Allow urgent administration cytarabine/hydrea/atra prior start treatment protocol . Allow previous administration one course HyperCVAD and/or FDA approve TKI . 2 . Zubrod performance status &lt; /= 3 . 3 . Adequate liver function ( bilirubin &lt; /= 3.0 mg/dl unless consider due tumor ) renal function ( creatinine &lt; /= 3.0 mg/dl , unless consider due tumor ) . 4 . No active coexisting malignancy life expectancy le 12 month due malignancy . 5 . All men woman childbearing potential participating study must agree use effective form birth control throughout duration treatment . 6 . Adequate cardiac function assess clinically 1 . Pregnant lactating woman . Women childbearing potential ( WOCB ) must blood urine pregnancy test within 7 day prior administration study drug . ( WOCB define woman undergone hysterectomy bilateral oophorectomy naturally postmenopausal least 24 consecutive month ) . 2 . Active Grade IIIIV cardiac failure define New York Heart Association criterion , uncontrolled angina MI within 6 month . 3 . Patients medical condition compromise ability complete study confound interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Lymphoblastic lymphoma</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Liposomal Vincristine</keyword>
	<keyword>Vincristine Sulfate Liposomes Injection</keyword>
	<keyword>Marqibo</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>ST1571</keyword>
	<keyword>NSC-716051</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>